Research programme: cancer therapeutics - Dracen Pharmaceuticals
Latest Information Update: 09 Jun 2023
At a glance
- Originator Dracen Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 15 May 2023 Early research in Cancer in USA (unspecified route) (Dracen Pharmaceuticals pipeline, May 2023)